Trials / Terminated
TerminatedNCT02134366
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- The Cooper Health System · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
Detailed description
First approved in the United States in 2011 for use in treating Lennox-Gastaut syndrome, clobazam is the only 1, 5-benzodiazepine that is currently approved for clinical use in the United States. In previous clinical trials clobazam has been shown to have a greater efficacy and produce fewer side effects in individuals when it's adverse event profile is compared to the traditional 1,4-benzodiazepines such as diazepam, lorazepam, and clonazepam. As a benzodiazepine, clobazam has been found to have anticonvulsant properties, and structural differences as a 1,5-benzodiazepines that appear to have a broader spectrum of anticonvulsant activity than those found in 1,4-benzodiazepines. In previous reports, clobazam has been seen to be effective in ether terminating or reducing both EPC in particular and partial status epilepticus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clobazam | Comparison of AED use in Epilepsia Partialis Continua |
| DRUG | Clonazepam | Comparison of AED use in Epilepsia Partialis Continua |
| DRUG | Lorazepam | Comparison of AED use in Epilepsia Partialis Continua |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2014-05-09
- Last updated
- 2018-05-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02134366. Inclusion in this directory is not an endorsement.